

## Overview


Vivia Biotech has developed accurate assays specifically tailored for characterizing the ex vivo pharmacological profile of your anti-proliferative CLL drug compounds, directly using authentic patient samples.

## Ex vivo proliferation assays for CLL patient samples: optimal for BTK or PI3K $\delta$ inhibitors

Vivia Biotech can enhance your CLL drug profiling processes by utilizing advanced assays employing state-of-the-art assays in a native environment, and gaining access to real biological samples from patients, thereby identifying the most effective drugs for CLL treatment.

Click  to  
learn more



Click  for custom  
assays in solid tumors

Click  for custom  
assays in hematological  
malignancies

## CLL Patient Samples Availability & Clinical Data Associated



### Fresh samples

-  >6,000 patient samples across Hem Malignancies
-  680 CLL samples evaluated
-  50 fresh CLL samples received annually



### Preserved samples

-  >315 CLL PB samples in stock
-  >60 CLL BM samples in stock

### Clinical information available

- ✓ Patient demographics
- ✓ Confirmed diagnosis
- ✓ Patient previous treatment history
- ✓ Cytogenetics and/or molecular characterization
- ✓ Additional information (to consult / on request)

Santiago Grisolia 2

28760 . Madrid . Spain

(+34) 91 129 3151

admin@viviabiotech.com


www.viviabiotech.com

**Overview**

Vivia Biotech has developed accurate assays specifically tailored for characterizing the ex vivo pharmacological profile of your anti-proliferative CLL drug compounds, directly using authentic patient samples.

**Vivia CLL proliferation assays**

To faithfully replicate the intricate in vivo microenvironment of CLL, we have formulated an ex vivo assay that optimally supports CLL proliferation and viability. This method utilizes a complete native peripheral blood or bone marrow CLL sample, combined with CpG + IL-2 + HS5 stromal cells, to closely mimic a lymph node environment.



Our key innovations supply sound pharmacology using real CLL patient samples.

Moreover, we can also design specific assays to combine your drug with other therapeutic agents.

**Vivia Biotech Peer-Reviewed Published Data on CLL Proliferation Assays**

Our CLL proliferation assays played a pivotal role in elucidating, for the first time, the antiproliferative effects of Idelalisib and Ibrutinib in patients with CLL ([www.viviabiotech.com/scientific-publications](http://www.viviabiotech.com/scientific-publications))

Click to learn more


Click for custom assays in solid tumors

Click for custom assays in hematological malignancies

www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 40), pp: 26019-26031

Research Paper

**A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia**



Santiago Grisolia 2

28760 . Madrid . Spain

(+34) 91 129 3151

admin@viviabiotech.com


www.viviabiotech.com

## Overview

Vivia Biotech has developed accurate assays specifically tailored for characterizing the ex vivo pharmacological profile of your anti-proliferative CLL drug compounds, directly using authentic patient samples.

Click  to  
learn more

Click  for custom  
assays in solid tumors

Click  for custom  
assays in hematological  
malignancies

Santiago Grisolia 2

28760 . Madrid . Spain

(+34) 91 129 3151

admin@viviabiotech.com

www.viviabiotech.com

## Highlights

- **TME's Impact on CLL Cells:** The TME plays a crucial role in promoting the survival and proliferation of CLL cells, contributing to disease progression and drug resistance.
- **Advanced Ex Vivo Proliferation Assay:** Our ex vivo proliferation assay incorporates TME stimuli, providing a more accurate simulation of in vivo interactions. This facilitates high-throughput pharmacological characterization under physiological conditions for anti-proliferative CLL drugs.
- **Preventing Resistance with Ex Vivo Assay:** Our ex vivo assay allows systematic preclinical testing of various combinations to effectively address potential resistance to BTK or PI3K $\delta$  inhibitors treatment.
- **Customized Assays for Drug Combinations:** We can customize assays to evaluate the most effective combination for your CLL drug with other therapeutic agents, including those undergoing clinical trials or approved for CLL, such as the recently FDA-approved Pirtobrutinib.
- **Versatility for Different Compounds:** Our proliferation assay is versatile, examining the effects of compounds like T Cell Engagers or NK Cell Engagers on proliferating cell subsets, either alone or combined with BTK or PI3K $\delta$  inhibitors.
- **Real-Time Identification and Separation:** Vivia proliferation assay enables high-throughput exploration of drug combinations and real-time identification and separation of proliferating and non-proliferating cells.
- **Contribution to Personalized Treatment:** Our goal is to contribute to predicting the ex vivo response to single or multiple drugs in each CLL patient requiring treatment.